NVO - NOVO NORDISK A S
Close
132.11
0 0%
Share volume: 4,768,400
Last Updated: Tue 24 Dec 2024 06:00:20 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.51%
PREVIOUS CLOSE
CHG
CHG%
$132.11
-43.31
0.49%
Fundamental analysis
48%
Profitability
64%
Dept financing
16%
Liquidity
52%
Performance
40%
Performance
5 Days
-14.24%
1 Month
-15.16%
3 Months
-29.28%
6 Months
-37.65%
1 Year
-13.63%
2 Year
32.40%
Key data
Stock price
$132.11
DAY RANGE
$87.08 - $88.96
52 WEEK RANGE
$86.53 - $148.15
52 WEEK CHANGE
-$13.61
DIVIDEND
$0.5126
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Lars F. Jørgensen
Region: US
Website: novonordisk.com
Employees: 54,400
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: novonordisk.com
Employees: 54,400
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Recent news